Efficacy of Osimertinib

Osimertinib is indicated for the adjuvant treatment after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation as detected by an FDA-approved test. Osimertinib is also indicated for the treatment of EGFR mutation-positive metastatic non-small cell lung cancer and previously treated EGFR T790M mutation-positive metastatic non-small cell lung cancer.

Recommendations for adjuvant treatment of early stage NSCLC Osimertinib The dose is 80 mg, taken orally once a day with or without food, until disease relapse or unacceptable toxicity occurs, or for 3 years. The primary efficacy outcome measure was disease-free survival (DFS) as determined by investigator assessment in patients with stage II IIIA non-small cell lung cancer. Compared with 19.6 months in the placebo group, patients in the osimertinib group did not reach the median DFS, which is a secondary efficacy outcome measure in the overall study population; compared with 27.5 months in the placebo group, patients in the osimertinib group did not reach the median.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.